| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. | Lancet Neurol | 2020 | 3.93 |
| 2 | Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD. | Acta Neuropathol Commun | 2016 | 0.90 |
| 3 | RGMa signal in Macrophages Induces Neutrophil-related Astrocytopathy in NMO. | Ann Neurol | 2022 | 0.75 |